35.75 +0.33 (0.93%)
After hours: 4:00PM EDT
|Bid||34.87 x 900|
|Ask||36.31 x 1200|
|Day's Range||35.24 - 36.22|
|52 Week Range||31.60 - 45.68|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Fortune's Sy Mukherjee interviews Livongo CEO Zane Burke and President Jennifer Schneider at NASDAQ Marketsite in Manhattan, NY.
Today, Livongo announced that Founder and Executive Chairman Glen Tullman will be honored with a Robert F. Kennedy Human Rights Ripple of Hope Award for his career focused on improving the safety, empathy, and efficiency of our healthcare system. The Ripple of Hope Award celebrates leaders of the international business, entertainment, and activist communities who have demonstrated a commitment to social change. Past honorees include President Barack Obama, Archbishop Desmond Tutu, Bono, George Clooney, and Robert F. Smith.
Livongo Health Inc (NASDAQ: LVGO) shares have bumped up more than 30% since the company went public at the end of July, raising interest in the digital health platform company. KeyBanc Capital Market's Donald Hooker initiated coverage of Livongo Health with an Overweight rating and $46 price target. Livongo uses technology to manage chronic disease treatment, mostly in patients with diabetes, and both analysts said the company’s business model appear to give it a long growth runway.
MOUNTAIN VIEW, Calif., Aug. 07, 2019 -- Livongo Health, Inc. (Nasdaq: LVGO) today announced it will hold a conference call on Thursday, September 5, 2019 at 8:00 a.m. Eastern.
MOUNTAIN VIEW, Calif., July 29, 2019 -- Livongo Health, Inc., (Nasdaq: LVGO) today announced the closing of its initial public offering of 14,590,050 shares of its common stock.
MOUNTAIN VIEW, Calif., July 24, 2019 -- Livongo Health, Inc. (Livongo) today announced the pricing of its initial public offering of 12,687,000 shares of its common stock at a.
The company's shares have been approved for listing on the Nasdaq under the ticker symbol LVGO. Kinnevik Online AB, which holds more than 5% of Livongo's outstanding capital stock, has expressed willingness to buy up to $20 million worth of shares or about 800,000 shares, the company said in the filing. Morgan Stanley, Goldman Sachs and JPMorgan are the lead underwriters for the offering.
For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . The IPO dates below are expected but not confirmed. Castle Biosciences Inc (NASDAQ: CSTL ) will issue more than 3.33 million ...